Capricor Therapeutics vs Keros Therapeutics
CAPR and KROS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAPR and KROS compare
Capricor Therapeutics is the larger company, worth 2.7 times as much as Keros Therapeutics ($554M against $204M).
Keros Therapeutics scores higher on the StockData Score (9 against 5 for Capricor Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAPR | KROS |
|---|---|---|
| Size and price | ||
| Market cap | $554M | $204M |
| Share price | $9.53 | $10.30 |
| Change, 1 year | 62.4% | −41.0% |
| Change, 5 years | 187% | −82.8% |
| Beta (5Y) | 1.18 | 1.11 |
| Employees | 231 | 78 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 5.1× |
| P/B | 2.6× | 0.7× (better) |
| FCF yield | −23.9% | −23.6% (better) |
| Fair value | – | $24.09 |
| Margin of safety | – | 57.3% |
| Growth | ||
| Revenue growth (TTM) | – | −83.4% |
| Net income growth (TTM) | – | −196% |
| EPS growth (TTM) | – | −282% |
| Profitability | ||
| Operating margin | – | −181% |
| Net margin | – | −153% |
| FCF margin | – | −119% |
| Return on equity | −100% | −12.6% (better) |
| Return on invested capital | – | −389% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.77 | 18.14 (better) |
| Altman Z-score | 0.06 | 2.37 (better) |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 67.6% | 101% |
| Held by insiders | 1.6% | 53.3% |
| Insider net buying, 12 months | −$8.4M | −$447K (better) |
| Short interest, % of float | 32.8% | 11.7% |
Go deeper
- CAPR stock overview
- CAPR income statement
- CAPR valuation and score
- KROS stock overview
- KROS income statement
- KROS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.